Pharmacological Management of Coagulation

Correct Answer

C — Tenecteplase

Rationale

Tenecteplase is classified as a fibrin-specific plasminogen activator that is administered as a single intravenous bolus with weight-based dosing — 30 to 50 mg determined by body weight in 10 kilogram increments. Alteplase is also fibrin-specific but requires a weight-based intravenous infusion over 60 to 90 minutes depending on the indication. Reteplase is administered as two fixed 10-unit intravenous boluses 30 minutes apart, not as a single bolus. Streptokinase is a non-fibrin-specific agent that produces a systemic lytic state and is given as a continuous infusion of 1.5 million units over 60 minutes.

Correct Answer

A — Reteplase

Rationale

Reteplase is classified as a deletion mutant of alteplase. Unlike alteplase, which contains five structural domains, reteplase retains only the kringle 2 domain and the catalytic serine protease domain, with the finger domain, epidermal growth factor domain, and kringle 1 domain deleted. This structural simplification reduces fibrin-binding affinity and increases the plasma half-life to approximately 13 to 16 minutes, permitting the double-bolus fixed-dose regimen of two 10-unit injections 30 minutes apart without weight adjustment. Tenecteplase is administered as a single weight-based bolus. Alteplase requires a continuous infusion. Streptokinase is a non-human protein, not a modified form of human tissue-type plasminogen activator.

Correct Answer

D — Streptokinase

Rationale

Streptokinase is classified as a non-enzymatic thrombolytic derived from beta-hemolytic streptococci. It has no intrinsic enzymatic activity but forms an equimolar 1:1 complex with plasminogen, inducing a conformational change that creates an active site capable of cleaving additional plasminogen molecules throughout the circulation. Because this activation occurs regardless of fibrin binding, streptokinase produces a systemic lytic state with depletion of circulating plasminogen, fibrinogen, and fibrin degradation product accumulation — the highest systemic bleeding risk of any thrombolytic. Being a foreign protein, streptokinase is antigenic and can generate neutralizing antibodies. Alteplase, tenecteplase, and reteplase are all recombinant human tissue-type plasminogen activator variants that are fibrin-specific and non-antigenic.

Correct Answer

B — Cryoprecipitate

Rationale

Cryoprecipitate is classified as the fibrinogen-rich fraction of fresh frozen plasma prepared by controlled thawing. Each unit contains approximately 150 to 250 milligrams of fibrinogen, along with factor VIII, factor XIII, von Willebrand factor, and fibronectin, in a volume of approximately 10 to 15 milliliters. This concentrated fibrinogen content makes it far more volume-efficient than fresh frozen plasma for fibrinogen replacement — fresh frozen plasma contains fibrinogen at approximately 2 to 3 milligrams per milliliter, while cryoprecipitate delivers 15 to 30 milligrams per milliliter. It is the preferred agent for fibrinogen replacement when thrombolytic therapy produces a systemic lytic state with fibrinogen depletion, targeting a fibrinogen level above 150 milligrams per deciliter. Four-factor prothrombin complex concentrate replaces vitamin K-dependent coagulation factors rather than fibrinogen. Platelet concentrate replenishes platelets but not fibrinogen or clotting factors.

Correct Answer

A — Epsilon-aminocaproic acid

Rationale

Epsilon-aminocaproic acid is classified as a synthetic lysine analogue antifibrinolytic. It competitively occupies the lysine-binding sites in the kringle domains of plasminogen, preventing plasminogen from attaching to fibrin at the clot surface. Because fibrin-bound plasminogen is the substrate for tissue-type plasminogen activator-mediated activation, blocking this binding effectively halts plasminogen activation and fibrinolysis. Tranexamic acid acts by the same mechanism and belongs to the same drug class, but epsilon-aminocaproic acid is the older, less potent agent requiring higher doses and longer infusion times. Protamine sulfate is a polycationic heparin reversal agent. Phytonadione is vitamin K1, a warfarin reversal agent. Andexanet alfa is a recombinant factor Xa decoy that reverses direct factor Xa inhibitors.

Correct Answer

B — Alteplase

Rationale

Alteplase is classified as a first-generation recombinant human tissue-type plasminogen activator. It is produced by recombinant DNA technology and is identical in structure to endogenous human tPA, containing all five structural domains: the finger domain, epidermal growth factor domain, kringle 1, kringle 2, and the serine protease catalytic domain. Reteplase and tenecteplase are second- and third-generation modified tPA variants, respectively — deletion mutant and point-mutated forms engineered from alteplase to improve pharmacokinetic properties. Streptokinase is not a tPA at all; it is a bacterial-derived non-enzymatic protein from beta-hemolytic streptococci. Tranexamic acid is a synthetic lysine analogue antifibrinolytic, not a thrombolytic agent.

Correct Answer

D — Tenecteplase has a plasma half-life of approximately 20 to 24 minutes — substantially longer than alteplase's 3 to 5 minutes — and approximately 80-fold greater resistance to plasminogen activator inhibitor-1, together allowing sustained therapeutic activity from a single weight-based bolus

Rationale

Tenecteplase is an engineered variant of alteplase with three amino acid substitutions that produce two key pharmacological advantages. First, specific substitutions in the finger and epidermal growth factor domains extend the plasma half-life from alteplase's 3 to 5 minutes to approximately 20 to 24 minutes, meaning plasma concentrations are maintained at therapeutically active levels well beyond the time required for clot contact and fibrinolysis initiation. Second, substitutions in the kringle 2 domain and catalytic domain produce approximately 80-fold greater resistance to inhibition by plasminogen activator inhibitor-1, the principal endogenous inactivator of tissue-type plasminogen activator. This resistance prevents rapid in vivo inactivation of tenecteplase at sites with high plasminogen activator inhibitor-1 concentrations, such as thrombus-rich coronary lesions. Together, these properties allow a single weight-based intravenous bolus to achieve complete thrombolysis without the need for the continuous infusion required by alteplase. The pivotal tenecteplase versus alteplase trial demonstrated non-inferiority to alteplase for 30-day mortality with less non-cerebral major bleeding. Tenecteplase retains high fibrin specificity comparable to alteplase and is not renally eliminated with a prolonged half-life.

Correct Answer

B — Prior streptococcal infection or prior streptokinase administration generates neutralizing antibodies against the foreign streptokinase protein, which bind and inactivate a subsequent therapeutic dose before it can form the plasminogen-activating complex

Rationale

Streptokinase is a non-human protein derived from beta-hemolytic streptococci. Because it is antigenically foreign, exposure — whether through streptococcal pharyngitis, skin infection, or prior therapeutic use — triggers an adaptive immune response with generation of immunoglobulin G antibodies directed against streptokinase. On subsequent exposure to a therapeutic dose, circulating anti-streptokinase antibodies bind and neutralize streptokinase molecules before they can form the 1:1 activating complex with plasminogen. If antibody titers are sufficiently high, a standard therapeutic dose may be completely neutralized, rendering the drug ineffective. Because antibody titers remain elevated for 6 to 12 months after exposure, repeat administration within this period is contraindicated. Recombinant tissue-type plasminogen activator variants (alteplase, tenecteplase, reteplase) are human proteins and are non-antigenic, allowing repeat administration without immune interference. The restriction does not involve plasminogen depletion, plasminogen activator inhibitor-1 upregulation, or receptor inactivation.

Correct Answer

A — Beyond 4.5 hours, irreversible infarction of the ischemic core is complete and the penumbral tissue that thrombolysis could salvage has died; restoring flow to already-infarcted tissue produces hemorrhagic transformation without functional benefit

Rationale

The 4.5-hour treatment window for alteplase in ischemic stroke reflects the biology of cerebral ischemia, not alteplase pharmacokinetics. Following arterial occlusion, the ischemic core — tissue receiving less than 10 to 20% of normal blood flow — undergoes irreversible infarction within minutes. Surrounding this core is the ischemic penumbra, tissue with compromised but not yet irreversibly damaged perfusion that can be salvaged if flow is restored quickly. Over time the penumbra progressively converts to infarct core. By 4.5 hours, in most patients without large-vessel occlusion amenable to mechanical thrombectomy, salvageable penumbra is substantially reduced or absent. Reperfusing already-infarcted brain exposes damaged vasculature and disrupted blood-brain barrier to arterial pressure without tissue rescue, producing hemorrhagic transformation and worsening outcomes. Alteplase itself retains pharmacological activity well beyond 4.5 hours — its half-life is 3 to 5 minutes but the constraint is tissue viability, not drug stability or access. Tenecteplase was approved for ischemic stroke in some jurisdictions using imaging-guided patient selection, extending treatment in patients with demonstrable salvageable penumbra. Alteplase does not undergo spontaneous hydrolysis in plasma and does not require blood-brain barrier penetration — it acts on intravascular thrombi from the luminal side.

Correct Answer

C — Reteplase is not approved for acute ischemic stroke because it has not been studied and demonstrated safe and effective in clinical trials for this indication; alteplase remains the only FDA-approved thrombolytic for ischemic stroke

Rationale

Regulatory approval for acute ischemic stroke thrombolysis requires demonstration of efficacy and acceptable safety in adequately powered randomized controlled trials specifically in stroke patients, because the risk-benefit profile of thrombolytics differs substantially between cardiac and cerebrovascular indications — the cerebral vasculature is uniquely sensitive to hemorrhagic transformation. Alteplase has been studied in multiple randomized controlled trials in stroke and is the only agent with FDA approval for this indication. Reteplase, while effective in ST-elevation myocardial infarction, has not undergone the stroke-specific clinical trial program required for approval. Structurally, reteplase's deletion of the finger domain reduces fibrin-binding affinity compared to alteplase, which may produce more systemic fibrinogenolysis — a pharmacological reason why its fibrin specificity and hemorrhagic profile in cerebral vessels have not been considered established. The fixed-dose regimen, half-life, and blood-brain barrier are not the pharmacological explanations for the approval restriction.

Correct Answer

D — Cryoprecipitate delivers fibrinogen at approximately 15 to 30 milligrams per milliliter, far more concentrated than fresh frozen plasma at 2 to 3 milligrams per milliliter, allowing the fibrinogen target to be reached with a much smaller infusion volume; it also contains factor VIII, factor XIII, and von Willebrand factor

Rationale

Cryoprecipitate is prepared by slow thawing of fresh frozen plasma at 1 to 6 degrees Celsius and collecting the precipitate that forms, which is rich in cryoglobulins. This process concentrates fibrinogen, factor VIII, factor XIII, von Willebrand factor, and fibronectin into a small volume of approximately 10 to 15 milliliters per unit. The fibrinogen concentration is approximately 15 to 30 milligrams per milliliter, compared to only 2 to 3 milligrams per milliliter in fresh frozen plasma. To raise fibrinogen from 80 to above 150 milligrams per deciliter in an adult, approximately 10 units of cryoprecipitate (total volume approximately 100 to 150 milliliters) achieves this with far less fluid than the many units of fresh frozen plasma that would be required. The additional factor VIII and factor XIII content provides supplementary hemostatic benefit in a patient with a thrombolytic-induced coagulopathy affecting multiple clotting proteins. Cryoprecipitate does not contain antifibrinolytic agents, and fresh frozen plasma does not activate thrombolytics. Cryoprecipitate still requires ABO compatibility in most guidelines, though it is less stringently required than for red cell products.

Correct Answer

B — Anti-thrombin activity requires longer heparin chains that form ternary complexes and are fully neutralized by protamine's ionic binding, while anti-factor Xa activity can be mediated by shorter pentasaccharide-containing fragments that partially escape protamine neutralization

Rationale

Protamine neutralizes heparin through ionic complex formation between the positively charged protamine and the negatively charged heparin sulfate groups. For thrombin inhibition, heparin must simultaneously bridge antithrombin III and thrombin in a ternary complex requiring a chain length of at least 18 saccharide units — these longer chains carry more negative charge and are efficiently captured by protamine. Low-molecular-weight heparin molecules containing these longer chains have their anti-thrombin activity completely neutralized. For factor Xa inhibition, only the critical pentasaccharide sequence binding antithrombin III is required, without ternary bridging to factor Xa. The shorter pentasaccharide-containing fragments of low-molecular-weight heparin carry less ionic charge per molecule and are less efficiently bound by protamine, so a fraction escapes neutralization. The result is complete reversal of anti-thrombin activity but only 60 to 75% reversal of anti-factor Xa activity. This is a clinically important limitation because residual anti-factor Xa activity may still contribute to bleeding risk. Enoxaparin's mechanism is entirely antithrombin III-dependent — it does not directly bind factor Xa.

Correct Answer

A — Acute traumatic injury triggers early fibrinolytic activation that destabilizes hemostatic clots; tranexamic acid blocks this fibrinolysis when given early, but after 3 hours the fibrinolytic phase resolves and the physiological state may shift toward procoagulant, making antifibrinolytic treatment potentially harmful rather than beneficial

Rationale

Severe traumatic injury triggers a biphasic response in the coagulation and fibrinolytic systems. In the early phase, release of tissue-type plasminogen activator from injured endothelium and consumption of plasminogen activator inhibitor-1 produces acute traumatic coagulopathy with a hyperfibrinolytic component that dissolves hemostatic clots before hemorrhage is controlled. Tranexamic acid, by blocking plasminogen-fibrin binding, suppresses this early fibrinolysis and stabilizes forming clots, reducing blood loss and mortality. As time passes from the traumatic event, the acute fibrinolytic activation subsides and the physiological balance shifts; at later time points, the coagulation system may be in a procoagulant state from tissue factor release, platelet activation, and coagulation factor consumption. In this setting, antifibrinolytic treatment may promote pathological microvascular thrombosis rather than beneficial hemostasis, explaining the potential harm observed with late administration in CRASH-2. The clinical implication is clear: tranexamic acid for traumatic hemorrhage must be given as soon as possible after injury and no later than 3 hours. Tranexamic acid's actual half-life is approximately 2 to 3 hours but this does not explain the benefit cutoff, and the drug is not hepatically inactivated to an antagonist metabolite.

Correct Answer

C — In most disseminated intravascular coagulation, fibrinolysis is a reactive protective response to microvascular fibrin deposition; inhibiting it worsens organ ischemia from microvascular thrombosis. In acute promyelocytic leukemia-associated disseminated intravascular coagulation, a primary hyperfibrinolytic state drives bleeding, making antifibrinolytic therapy appropriate

Rationale

Disseminated intravascular coagulation involves simultaneous activation of coagulation and fibrinolysis. In most etiologies — sepsis, trauma, obstetric complications — fibrinolysis is a secondary reactive response to the massive fibrin deposition that causes microvascular thrombosis and organ failure. In this context, fibrinolysis is protective: it attempts to dissolve microvascular fibrin to restore organ perfusion. Inhibiting this fibrinolysis with tranexamic acid would allow microvascular thrombosis to worsen, increasing ischemic organ damage. In disseminated intravascular coagulation associated with acute promyelocytic leukemia, the pathophysiology is distinct: leukemic cells express fibrinolytic activators on their surface, producing a primary hyperfibrinolytic state where excessive plasmin generation drives hemorrhage before coagulation activation is the dominant problem. Here, fibrinolysis is pathological rather than protective, and tranexamic acid is beneficial in controlling the hemorrhagic manifestations. This mechanistic distinction — reactive fibrinolysis versus primary fibrinolysis — determines when antifibrinolytic therapy helps or harms in disseminated intravascular coagulation.

Correct Answer

B — No — in septic disseminated intravascular coagulation, fibrinolysis is a reactive protective response to microvascular fibrin deposition; blocking it with tranexamic acid risks worsening organ ischemia from microvascular thrombosis rather than improving outcomes

Rationale

In sepsis-associated disseminated intravascular coagulation, systemic infection activates the coagulation cascade, producing widespread microvascular fibrin deposition that impairs organ perfusion. The fibrinolysis that occurs simultaneously — evidenced by elevated fibrin degradation products — is a reactive physiological response attempting to dissolve this microvascular fibrin and restore flow. Inhibiting this fibrinolysis with tranexamic acid removes the counterbalancing protective mechanism, allowing microvascular fibrin to accumulate further and worsening organ ischemia, particularly in the kidney, lung, and liver. Clinical evidence does not support antifibrinolytic therapy in septic disseminated intravascular coagulation, and guidelines recommend against it. The appropriate management in this patient is treatment of the underlying sepsis and source control, with supportive measures including fresh frozen plasma, cryoprecipitate, and platelet transfusion to correct the coagulopathy causing oozing. The contrast case is disseminated intravascular coagulation in acute promyelocytic leukemia, where primary — not reactive — fibrinolysis drives bleeding, making tranexamic acid appropriate. Elevated fibrin degradation products alone do not indicate pathological fibrinolysis requiring drug treatment; they are expected in any form of disseminated intravascular coagulation.

Correct Answer

D — Stop the alteplase infusion immediately, administer cryoprecipitate to restore fibrinogen above 150 milligrams per deciliter, and give tranexamic acid to inhibit ongoing systemic plasminogen activation

Rationale

Serious systemic bleeding during alteplase administration — ecchymoses, hypotension, and fibrinogen depletion to 75 milligrams per deciliter — indicates that the drug's systemic fibrinolytic effect has produced a lytic state beyond its intended fibrin-specific action. The correct response is to stop the infusion immediately to prevent further fibrinogen depletion. Cryoprecipitate (10 units) is the preferred product for fibrinogen replacement because it delivers fibrinogen at approximately 15 to 30 milligrams per milliliter — far more concentrated than fresh frozen plasma — allowing the target fibrinogen level above 150 milligrams per deciliter to be achieved with a small infusion volume. Tranexamic acid, a lysine analogue antifibrinolytic, is added to block ongoing plasminogen-fibrin binding and suppress continued plasmin generation from any residual alteplase still in circulation. Fresh frozen plasma alone is inadequate for rapid fibrinogen replacement. Dose reduction is not appropriate for serious bleeding — the infusion must stop. The neurological exam being unchanged from baseline supports that no intracranial hemorrhage has occurred yet, but prompt reversal is essential to prevent progression.

Correct Answer

C — Current anticoagulant therapy with an INR above 1.7 is an absolute contraindication to systemic thrombolysis because the combined fibrinolytic and anticoagulant effect substantially increases the risk of life-threatening intracranial hemorrhage

Rationale

Systemic thrombolysis with alteplase carries an inherent risk of intracranial hemorrhage through plasmin-mediated dissolution of fibrin in existing hemostatic plugs and cerebral vessel walls, as well as systemic fibrinogenolysis that impairs clot formation at sites of vascular breach. When a patient is already anticoagulated with an elevated INR — reflecting depletion of vitamin K-dependent coagulation factors — adding a thrombolytic agent removes the final hemostatic barrier at the cerebral vasculature. Current anticoagulation with INR above 1.7, oral anticoagulant use, or therapeutic heparin with elevated aPTT are all listed as absolute contraindications to alteplase in acute pulmonary embolism and ischemic stroke protocols precisely because the combined coagulopathy creates unacceptable intracranial hemorrhage risk. If the clinical situation demands revascularization — as it does in massive PE with hemodynamic compromise — surgical embolectomy or catheter-directed therapy should be considered. Warfarin does not affect plasminogen function or alteplase clearance, and the mechanical valve has no pharmacokinetic relevance to alteplase distribution.

Correct Answer

B — Elevated blood pressure in the setting of thrombolysis increases the risk of hemorrhagic transformation by exposing cerebrovascular walls — already disrupted by ischemia and the fibrinolytic lytic state — to higher transmural pressure, converting ischemic injury to hemorrhage

Rationale

Ischemic stroke compromises the blood-brain barrier and the structural integrity of cerebrovascular walls in the affected territory. Alteplase's fibrinolytic action — dissolving fibrin clots but also producing systemic plasmin generation and local fibrinogenolysis — further impairs the hemostatic capacity of these already-vulnerable vessels. If blood pressure remains markedly elevated during or after thrombolysis, the high transmural pressure applied to weakened vessel walls that lack adequate hemostatic clotting capacity substantially increases the risk of hemorrhagic transformation of the ischemic infarct. This is why guidelines require blood pressure below 185/110 mmHg before starting alteplase and below 180/105 mmHg for at least 24 hours afterward. Intravenous labetalol or nicardipine are commonly used to achieve this target rapidly. The blood pressure threshold is not arbitrary — data from stroke thrombolysis trials confirm that patients treated outside this blood pressure window have significantly higher rates of symptomatic intracranial hemorrhage. The requirement is purely about hemorrhagic risk management and has no pharmacokinetic basis related to alteplase bioavailability, receptor binding, or cerebrovascular distribution.